IGM BiosciencesIGMS
About: IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Employees: 54
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3,100% more call options, than puts
Call options by funds: $32K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
4% less funds holding
Funds holding: 83 [Q4 2024] → 80 (-3) [Q1 2025]
11.8% less ownership
Funds ownership: 63.61% [Q4 2024] → 51.82% (-11.8%) [Q1 2025]
19% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 26
85% less capital invested
Capital invested by funds: $133M [Q4 2024] → $20.5M (-$112M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Truist Securities Asthika Goonewardene | 17%downside $1 | Hold Maintained | 11 Jun 2025 |
Financial journalist opinion
